LC–MS/MS determination of HY072808, a novel candidate for treating atopic dermatitis, and its active metabolite: Application to a first‐in‐human pharmacokinetic study
Wu J, Zheng L, Zhang Q, Zhang Q, Qin H, Zhou R, Chu Z, He G, Wang L, Hu W. LC–MS/MS determination of HY072808, a novel candidate for treating atopic dermatitis, and its active metabolite: Application to a first‐in‐human pharmacokinetic study. Biomedical Chromatography 2022, 37: e5542. PMID: 36330676, DOI: 10.1002/bmc.5542.Peer-Reviewed Original ResearchMeSH KeywordsChromatography, LiquidDermatitis, AtopicHumansPhosphodiesterase 4 InhibitorsReproducibility of ResultsTandem Mass SpectrometryConceptsAtopic dermatitisClinical developmentActive metabolitePhosphodiesterase 4 inhibitorNovel phosphodiesterase 4 inhibitorClinical trialsSimple liquid-liquid extraction methodTopical administrationHealthy humansSensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) methodHuman pharmacokinetic studiesPg/Liquid chromatography-tandem mass spectrometry methodChromatography-tandem mass spectrometry methodPositive ion modeLiquid chromatographic separationPharmacokinetic studyPlasma samplesMultiple reaction monitoringLiquid-liquid extraction methodMass spectrometry methodLC-MS/MS determinationDermatitisMS/MS quantificationIon mode